Hogan Lovells Advises Recordati on Acquisition of Inrebic Manufacturing and Commercialization Rights in Japan

Hogan Lovells represented Recordati in connection with agreements to acquire from Impact Biomedicines, a company wholly owned by Bristol‑Myers Squibb K.K., the rights to manufacture and commercialize Inrebic in Japan. The transaction transfers to Recordati the production and commercialization rights for Inrebic (generic name: fedratinib hydrochloride hydrate) in the Japanese market. Inrebic is a pharmaceutical treatment for myelofibrosis. Hogan Lovells represented Recordati with a cross‑practice, multi‑jurisdictional team composed by: Francesco Stella (Partner, lead and coordinator), Penny Powell (Partner, lead and coordinator), Bea Watts (Associate, London), James Furneaux (Associate, London), Frederick Ch'en (Partner, Tokyo), Hiroto Imai (Partner, Tokyo), Audrey Reed (Partner, Washington), Cullen Taylor (Partner, Washington). Recordati in‑house legal department represented Recordati with a team composed by: Bibianne Bon (Chief Legal Officer) and Giuseppe Colangelo (Legal Counsel).

Hogan Lovells Advises Recordati on Acquisition of Inrebic Manufacturing and Commercialization Rights in Japan

Read the full story